CompletedPhase 2NCT00444743

Phase 2 Study of MM-093 to Treat Patients With Uveitis

Studying Uveitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Merrimack Pharmaceuticals
Principal Investigator
Dr. Stephen Foster
Massachusetts Eye Research and Surgery Institute
Intervention
MM-093(drug)
Enrollment
20 target
Eligibility
18 years · All sexes
Timeline
2007

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00444743 on ClinicalTrials.gov

Other trials for Uveitis

Additional recruiting or active studies for the same condition.

See all trials for Uveitis

← Back to all trials